Prognostic significance of macrophage migration inhibitory factor expression in cancer patients

Koh, Hyun Min; Kim, Dong Chul

doi:10.1097/md.0000000000021575

Cited by 11 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MIF expression and secretion is elevated in most solid and hematogenous cancers and high MIF expression is a negative prognostic indicator in several cancer types (9). The extent of MIF expression is dependent on the tumor tissue type, stage, and grade among other factors (10). For example, intratumoral MIF is increased-versus normal tissue-three-and five-fold in endometrial carcinoma and non-small cell lung carcinoma (11,12), respectively, ten times in hepatocellular carcinoma (13) and sixty times in colorectal cancer (14).…”

Section: Mif's Mechanisms Of Actionmentioning

confidence: 99%

MIF-Dependent Control of Tumor Immunity

Noe

Mitchell

2020

Front. Immunol.

View full text Add to dashboard Cite

Initially identified as a T lymphocyte-elicited inhibitor of macrophage motility, macrophage migration inhibitory factor (MIF) has since been found to be expressed by nearly every immune cell type examined and overexpressed in most solid and hematogenous malignant cancers. It is localized to both extracellular and intracellular compartments and physically interacts with more than a dozen different cell surface and intracellular proteins. Although classically associated with and characterized as a mediator of pro-inflammatory innate immune responses, more recent studies demonstrate that, in malignant disease settings, MIF contributes to anti-inflammatory, immune evasive, and immune tolerant phenotypes in both innate and adaptive immune cell types. This review will summarize the studies describing MIF in tumor-specific innate and adaptive immune responses and attempt to reconcile these various pleiotropic functions in normal physiology.

show abstract

Section: Mif's Mechanisms Of Actionmentioning

confidence: 99%

MIF-Dependent Control of Tumor Immunity

Noe

Mitchell

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…A recent meta‐analysis revealed that MIF overexpression is associated with a poor prognosis and lower survival rates in cancer patients. Mechanistically, MIF activates the MAPK and PI3K pathways, which are crucial for regulating essential cellular functions, including cell proliferation, differentiation, apoptosis, and survival 32 . These pathways are also known to play a role in cancer development and progression.…”

Section: Discussionmentioning

confidence: 99%

“…Mechanistically, MIF activates the MAPK and PI3K pathways, which are crucial for regulating essential cellular functions, including cell proliferation, differentiation, apoptosis, and survival. 32 These pathways are also known to play a role in cancer development and progression. Our findings highlight the importance of MIF in CAF signalling and its potential as a prognostic factor and therapeutic target in cancer.…”

Section: Discussionmentioning

confidence: 99%

Histone modification‐linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter

Xiong,

Liang,

Sun

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Ovarian cancer (OC) is a deadly disease with limited treatment options and poor overall survival rates. This study aimed to investigate the role of histone modification‐related genes in predicting the prognosis of OC patients. Transcriptome data from multiple cohorts, including bulk RNA‐Seq data and single‐cell scRNA‐Seq data, were collected. Gene set enrichment analysis was used to identify enriched gene sets in the histone modification pathway. Differentially expressed genes (DEGs) between histone modification‐high and histone modification‐low groups were identified using Lasso regression. A prognostic model was constructed using five selected prognostic genes from the DEGs in the TCGA‐OV cohort. The study found enrichment of gene sets in the histone modification pathway and identified five prognostic genes associated with OC prognosis. The constructed risk score model based on histone modification‐related genes was correlated with immune infiltration of T cells and M1 macrophages. Mutations are more prevalent in the high‐risk group compared to the low‐risk group. Several drugs were screened against the model genes. Through in vitro experiments, we confirmed the expression patterns of the model genes. LBX2 facilitates the proliferation of OC. Histone modification‐related genes have the potential to serve as biomarkers for predicting OC prognosis. Targeting these genes may lead to the development of more effective therapies for OC. Additionally, LBX2 represents a novel cell proliferation promoter in OC carcinogenesis.

show abstract

“…Macrophage migration inhibitory factor (MIF), a pivotal cytokine, is widely expressed and released by many types of cells, including macrophages, endothelial cells, and tumor cells. 2,3 It regulates a variety of cellular and biological functions, thereby contributing to the control of cell fate. 4 Mounting evidence has demonstrated the importance of MIF in cancer cells, in which the overexpressed MIF results in the manipulation of the immune system to protect cancer cells, inducing cell proliferation and angiogenesis.…”

mentioning

confidence: 99%

“…Visualization of these biomarkers is particularly important for understanding their biological roles in cellular events. Macrophage migration inhibitory factor (MIF), a pivotal cytokine, is widely expressed and released by many types of cells, including macrophages, endothelial cells, and tumor cells. , It regulates a variety of cellular and biological functions, thereby contributing to the control of cell fate . Mounting evidence has demonstrated the importance of MIF in cancer cells, in which the overexpressed MIF results in the manipulation of the immune system to protect cancer cells, inducing cell proliferation and angiogenesis. , Elevated MIF activity has also been closely connected with the metastatic potential and the alteration of tumor-suppressive pathways. , Tumor tissues, such as liver, lung, breast, colon, and brain-derived tumors, have been found to significantly overexpress MIF compared to normal cells .…”

mentioning

confidence: 99%

In Vivo Imaging of the Macrophage Migration Inhibitory Factor in Liver Cancer with an Activity-Based Probe

2021

View full text Add to dashboard Cite

The macrophage migration inhibitory factor (MIF), a vital cytokine and biomarker, has been suggested to closely associate with the pathogenesis of liver cancer. However, a simple and effective approach for monitoring the change and distribution of cellular MIF is currently lacking and urgently needed, which could be helpful for a better understanding of its role in the progression of cancer. Herein, we report a novel activity-based probe, TPP2, which allows for direct labeling and imaging of endogenous MIF activity within live cells, clinical tissues, and in vivo in a mouse model of liver cancer. With this probe, we have intuitively observed the dynamic change of intracellular MIF activity by both flow cytometry and confocal imaging. We further found that TPP2 permits the identification and distinguishing of liver cancer in vitro and in vivo with high sensitivity and selectivity toward MIF. Our observations indicate that TPP2 could provide a promising new imaging approach for elucidating the MIF-related biological functions in liver cancer.

show abstract

Prognostic significance of macrophage migration inhibitory factor expression in cancer patients

Cited by 11 publications

References 16 publications

MIF-Dependent Control of Tumor Immunity

MIF-Dependent Control of Tumor Immunity

Histone modification‐linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter

In Vivo Imaging of the Macrophage Migration Inhibitory Factor in Liver Cancer with an Activity-Based Probe

Contact Info

Product

Resources

About